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Systemic lupus erythematosus (SLE) is considered to be the prototypic autoimmune disease, with a complex genetic architecture influ-
enced by environmental factors. We sought to replicate a putative association at 11p13 not yet exceeding genome-wide significance
(p < 5 3 108) identified in a genome-wide association study (GWAS). Our GWA scan identified two intergenic SNPs located between
PDHX and CD44 showing suggestive evidence of association with SLE in cases of European descent (rs2732552, p ¼ 0.004, odds ratio
[OR] ¼ 0.78; rs387619, p ¼ 0.003, OR ¼ 0.78). The replication cohort consisted of >15,000 subjects, including 3562 SLE cases and
3491 controls of European ancestry, 1527 cases and 1811 controls of African American (AA) descent, and 1265 cases and 1260 controls
of Asian origin. We observed robust association at both rs2732552 (p ¼ 9.03 3 108, OR ¼ 0.83) and rs387619 (p ¼ 7.7 3 107, OR ¼
0.83) in the European samples with pmeta ¼ 1.82 3 109 for rs2732552. The AA and Asian SLE cases also demonstrated association at
rs2732552 (p ¼ 53 103, OR ¼ 0.81 and p ¼ 4.33 104, OR ¼ 0.80, respectively). A meta-analysis of rs2732552 for all racial and ethnic
groups studied produced pmeta ¼ 2.363 1013. This locus contains multiple regulatory sites that could potentially affect expression and
functions of CD44, a cell-surface glycoprotein influencing immunologic, inflammatory, and oncologic phenotypes, or PDHX, a subunit
of the pyruvate dehydrogenase complex.Systemic lupus erythematosus (SLE [MIM 152700]) is
a chronic, heterogeneous autoimmune disorder character-
ized by inflammation, loss of tolerance to self-antigens,
and dysregulated interferon responses. Defining features
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Table 1. Summary of Samples Genotyped
Populations Number of Samples Case Control Unknown Disease Status Male Female Unknown Gender
African Americans 3462 1569 1893 0 723 2733 6
Asians 2676 1328 1348 0 296 2380 0
Europeans 8066 4248 3818 0 1642 6403 21
Gullah 286 155 131 0 34 252 0
Hispanics 1383 1033 350 0 160 1222 1
Amerindians 1126 589 537 0 67 1,057 2
Unknown 4 0 0 4 0 4 0
Total 17,003 8922 8077 4 2922 14,051 30studies (GWAS), have begun to elucidate the complex
genetic architecture of SLE with identification of >30 risk
loci.1 These studies have collectively established the
importance of several pathways in SLE, including innate
immune responses, activation of lymphocytes, and
immune complex clearing.1
Althoughmany new loci have been identified as contrib-
uting to the pathogenesis of SLE, they collectively do not
explain all the risk contributed by heritable factors. For
example, recessive effects remain a challenge to detect in
the studies conducted to date. Much larger sample sizes
(>10,000 cases and 10,000 controls) are needed to detect
such effects. Rare or private mutations are also difficult to
detect under recently used study designs. The majority of
established genetic effects to date have been identified
through studies in cohorts of European descent. There
are distinct clinical differences between racial groups,
including higher risk in African Americans and Asians for
developing more severe disease. Previous studies have
also suggested that risk haplotypes between groups differ,
as illustrated by ITGAM (MIM 120980), in which the differ-
ences in haplotype structure were used to identify the
causal variant.2
In this study, we sought to replicate a suggestive associa-
tion at 11p13 not reaching genome-wide significance (p <
5 3 108) in our previous GWAS3 that had also been iden-
tified in a linkage study of SLE when evaluating multiplex
pedigrees with thrombocytopenia.4 This region contains
a gene, CD44 (MIM 107269), that has been well studied
at the protein level in relation to SLE risk, as well as
many other inflammatory conditions. Here we replicate
association with two SNPs identified in the GWAS just telo-
meric to CD44.
The initial GWAS was performed with the Affymetrix
Genome-wide Human SNP array 5.0 with a sample size
of 431 European SLE cases and 2,155 European controls,
as described in Graham et al., 2008.3 Themultiethnic repli-
cation study consisted of 17,003 total samples (8,922 SLE
cases and 8,077 controls), which included self-reported
African Americans, Asians, Europeans, Gullahs, Hispanics,
and Amerindians (Table 1). The samples were assembled at
the Oklahoma Medical Research Foundation (OMRF) after84 The American Journal of Human Genetics 88, 83–91, January 7, 20collection through multiple institutions around the
world, following ethics committee approval and informed
consent. All cases fulfilled American College of Rheuma-
tology criteria for the classification of SLE.5
The replication data were generated with the Illumina
iSelect technology at the OMRF. A total of 119 SNPs en-
compassing CD44 and within the linkage peak previously
observed at 11p13 (2 Mb interval) plus 347 ancestral-infor-
mative markers (AIMs) typed throughout the genome were
evaluated. SNPs used in the analysis were required to pass
stringent quality control criteria that includedwell-defined
cluster scatter plots,>90% call rates across the entire study,
Hardy-Weinberg proportions with p> 0.01 in controls and
p > 0.0001 in cases, total proportion missing <5%,
and p > 0.05 for differential missingness between cases
and controls.
Samples with a <90% call rate or increased heterozy-
gosity (>5 standard deviations from the mean) were
excluded from the analysis. The remaining samples were
then evaluated for duplicates or related individuals, and
one individual from each pair was removed if the propor-
tion of alleles shared identity by descent was > 0.4.
Samples were assessed for mismatches between reported
gender and genetic data. Assigned males were required to
have chromosomal X heterozygosity % 10% and be
heterozygous at rs2557523, because the G allele for this
SNP is only observed on the Y chromosome, and the A
allele appears only on the X chromosome. Assigned
females were required to have chromosomal X heterozy-
gosity > 10% and be homozygous at rs2557523.
Finally, genetic outliers were removed from further anal-
ysis, as determined by principal component analysis (PCA)
and admixture estimates (Figure 1).6,7 Price et al. utilized
PCA for correcting for population stratification by inferring
continuous axes of genetic variation on genotype data
that is implemented in EIGENSTRAT software.6 Another
method, combining Bayesian and sampling-theory
approaches, has been proposed to estimate admixture
proportions inmultiple populations7–9 andhas been imple-
mented in ADMIXMAP software. Both EIGENSTRAT6 and
ADMIXMAP8,9 were used to identify population strata
within the samples with AIMs, with both yielding similar11
Figure 1. Principal Components Identify Continental Ancestry
Plot of the first two principal components identifying continental
population substructure within our sample set before quality
control (QC) (A) with 17,003 subjects and after QC (B) with
15,490 subjects. Each circle represents an individual sample, and
colors represent the populations based on self-report.results. The AIMs were selected to distinguish four conti-
nental ancestral populations: Africans, Europeans, Amer-
ican Indians, and East Asians (Figure 1).10,11 We utilized
principal components from EIGENSTRAT outputs to iden-
tify outliers from each population cluster. After quality
control, a total of 1,139 samples was excluded (Table 2).
Final numbers of subjects included in analyses were
15,490 for replication and 18,076 with the GWAS samples
included (Table 3).The ATo test for SNP-SLE association in the replication study,
we performed logistic regression, as implemented in
PLINK.12 The additive, dominant, and recessive models
were calculated while adjusting for the first three principle
components and gender. Models were also analyzed with
the ancestry estimates provided by ADMIXMAP, with no
observable difference. Meta-analyses of the SNPs observed
in both the GWAS and the multiethnic study were calcu-
lated with a weighted Z score (Stouffer’s Ztrend), as imple-
mented in METAP.13 Here the weight is the square root of
the sample size for each group. This controls for differences
in sample size between studies when combining.
Our previously published GWAS identified two SNPs
in strong linkage disequilibrium (LD, r2 ¼ 0.94) located
~74 kb telomeric to CD44, showing suggestive evidence of
association with European SLE cases (rs2732552, p ¼
0.004, odds ratio [OR] ¼ 0.78, 95% confidence interval
[CI] ¼ 0.69–0.93; rs387619, p ¼ 0.003, OR ¼ 0.78, 95%
CI¼ 0.68–0.91). In the current independent study, we eval-
uated this region in a large multiethnic case-control collec-
tion of 17,003 subjects (before quality control; Table 1).
We observed robust association at both rs2732552 (p ¼
9.033 108, OR¼ 0.83, 95%CI¼ 0.77–0.88) and rs387619
(p ¼ 7.7 3 107, OR ¼ 0.83, 95% CI ¼ 0.77–0.90) in the
European samples (Table 4 and Figure 2A). Meta-analyses
of these two SNPs between our current European data set
and that used in the GWAS, accounting for differences in
sample size with a weighted Z score, produced results that
surpass genome-wide thresholds for significance and
yielded a pmeta ¼ 1.82 3 109 (OR ¼ 0.82, 95% CI ¼ 0.76–
0.88) for rs2732552 and a pmeta ¼ 1.46 3 108 (OR ¼ 0.82,
95% CI ¼ 0.76–0.88) for rs387619 (Table 4 and Figure 2A).
The African American and Asian SLE cases also demon-
strated association at rs2732552 (p ¼ 5 3 103, OR ¼ 0.81,
95% CI ¼ 0.70–0.94 and p ¼ 4.3 3 104, OR ¼ 0.80, 95%
CI ¼ 0.70–0.91, respectively). The Asian SLE cases were
associated with rs387619 (p ¼ 0.001, OR ¼ 0.8, 95% CI ¼
0.70–0.91), whereas the African American SLE cases
were not, consistent with differences in the haplotype
patterns between racial groups (Table 4; Figure 2A; Fig-
ure 3). Meta-analysis at rs2732552 between Europeans,
Asians, African Americans, and the GWAS produced
pmeta ¼ 3.00 3 1013. In this study, no evidence of associ-
ation (p < 0.05) was observed in Hispanic, Gullah, or
Amerindian subjects, possibly because of small sample
sizes relative to the other races and/or ethnicities, clinical
and/or genetic heterogeneity, or reduced correlation
between tested markers and one or more causal variants.
When evaluating all ethnic and racial groups evaluated
within this study, meta-analysis yielded a pmeta ¼ 2.36 3
1013. Several of the subphenotypes comprising the SLE
criteria, including thrombocytopenia, were also tested for
association with these SNPs. No significant relationships
were observed, possibly because of incomplete data.
These two SNPs flank the boundaries of an ~14 kb haplo-
type block observed in Europeans and Asians with r2> 0.9,
but with only r2 < 0.1 in African Americans (Figure 2A andmerican Journal of Human Genetics 88, 83–91, January 7, 2011 85
Table 2. Summary of Samples Remaining after QC
Populations Number of Samples Case Control Unknown Disease Status Male Female Unknown Gender
African Americans 3338 1527 1811 0 695 2643 0
Asians 2525 1265 1260 0 253 2272 0
Europeans 7053 (7427)a 3562 (3936)a 3491 0 1495 5932 0
Gullah 275 152 123 0 33 242 0
Hispanics 1297 961 336 0 149 1148 0
Amerindians 1002 531 471 0 58 944 0
Unknown 0 0 0 0 0 0 0
Total 15,490 (15864)a 7998 (8372)a 7492 0 2683 13,181 0
a Number of European cases before removing 374 samples to render replication independent from GWAS.Figure 3). To increase the informativeness of this haplo-
type, we conducted imputation in all three ethnic groups
over a 2 Mb region. Imputation of the replication data
across chromosome 11 (35–37 Mb) was performed with
IMPUTE2, with the HapMap Phase III and 1000 Genomes
Project as reference panels for African Americans, Asians,
and Europeans (Table 5).14–16 Imputation is a method
used to infer genotypes by using other correlated SNPs as
proxies for those not genotyped. Subject genotypes are
compared to a reference panel of all the SNPs genotyped
within the study and those desired to be imputed.
IMPUTE2 was selected because it can combine two refer-
ence panels in a single imputation analysis that will
increase genotype-imputation accuracy. IMPUTE2 calcu-
lates posterior probabilities for the three possible geno-
types (AA, AB, BB).
Imputed genotypes had to meet or exceed a probability
and certainty score of >0.9, and the quality control criteria
described above had to be included in the analyses.
However, we accepted genotype call rates for imputed
SNPs at >70% in the African Americans because of the
small LD blocks. After quality control, a total of 238 SNPs
was imputed in the European replication cohort within
a 0.5 Mb region. Because no significant associations were
observed outside the 14 kb haplotype in Europeans, impu-
tation for Asians and African American samples was per-
formed between rs2732552 and rs387619. After quality
control, imputed data were included for 24 SNPs in the
Asian and 9 SNPs in the African American data sets.
Several imputed SNPs demonstrated association with
disease (Table 4 and Figure 2B). The most statistically signi-
ficant imputed marker among Europeans was rs2553772
(p ¼ 7.35 3 108). This SNP was also significantly associ-Table 3. Summary of Sample Data Sets
Dataset Cases Controls Total
GWAS 431 2155 2586
Multiethnic replication 7998 7492 15,490
Combined 8429 9647 18,076
86 The American Journal of Human Genetics 88, 83–91, January 7, 20ated with SLE in the Asians (p ¼ 1.05 3 104) but did
not pass our quality control criteria in African Americans.
However, a neighboring SNP, rs2785202, was found to
be significant in all three populations (Table 4 and
Figure 2C).
Bioinformatics database mining revealed that this region
is conserved across species and has substantial regulatory
potential within seven mammalian species, supported by
experimental evidence using chromatin immunoprecipita-
tion followed by sequencing (ChIP-Seq). The ENCODE
project recently cataloged transcription factor binding
sites and chromatin modification throughout the genome
with ChIP-Seq in several different cell lines.17 The most
strongly associated SNPs after imputation within our
study flank two transcription factor binding sites identified
in a myelogenous leukemia cell line: E2F6 (35,041,517–
35,041,963 base pairs [bp]; peak binding at 35,041,
776 bp) and c-Jun (35,041,681–35,042,886 bp; peak
binding at 35,041,895 bp; Figure 1C).17 Another region
of interest includes an NF-kB (35,044,973–35,045,701 bp)
binding site identified in a lymphoblastoid cell line, with
the peak binding localized at 35,045,460 bp, only 46 bases
away from rs2785201 (Figure 2C). Studies of multiple cell
lines have demonstrated that the regions spanning
35,043,876–35,047,875 bp (H3K4me1) and 34,998,301–
35,641,975 bp (H3K27me3) are H3 histone interaction
sites shown to be regulated by histone methylation,
which can influence chromatin structure, resulting in tran-
scriptional silencing or enhanced activity (Figure 2C).
Further evaluation will be required to determine whether
one or more of these regulatory elements contributes to
SLE risk.
The genetic association with SLE established in this
study lies between PDHX and CD44, both of which have
been previously implicated in autoimmune or inflamma-
tory conditions. PDHX (MIM 608769) is ~79 kb in length
with 11 exons and encodes for the E3 subunit of the pyru-
vate dehydrogenase (PDH) complex involved in the
conversion of pyruvate to acetyl coenzyme A, which links
glycolysis and the Krebs cycle.18 Interestingly, approxi-
mately 95% of primary biliary cirrhosis patients produce11
Table 4. Results of Observed and Imputed SNPs at 11p13 Telomeric of CD44a
SNP
Position
(Mb)
European Asian African American
Allelesb MAF GWAS p OR (95% CI)c pmeta (OR, 95% CI) Alleles
b MAF p OR (95% CI)c Allelesb MAF p OR (95% CI)c
rs2732552 35.041168 C/T 0.43 4.00E03 9.03E08 0.83 (0.77–0.89) 1.82E09 (0.82, 0.76–0.88) C/T 0.27 4.31E04 0.80 (0.71–0.90) T/C 0.34 5.36E03 0.81 (0.94–0.70)
rs2785202 35.041411 C/G 0.42 8.04E08 0.83 (0.77–0.89) C/G 0.27 4.09E04 0.80 (0.70–0.90) G/C 0.36 8.24E04 0.77 (0.66–0.90)
rs2553772 35.042029 G/T 0.43 7.35E08 0.82 (0.77–0.88) G/T 0.24 1.05E04 0.76 (0.66–0.87) N/A N/A N/A N/A
rs2732550 35.044894 G/T 0.42 3.21E07 0.83 (0.77–0.89) G/T 0.24 1.55E04 0.76 (0.66–0.88) G/T 0.01 0.060 0.44 (0.19–1.03)
rs2732549 35.044975 A/G 0.43 1.58E07 0.83 (0.77–0.89) A/G 0.24 1.34E04 0.76 (0.66–0.88) N/A N/A N/A N/A
rs2732547 35.045259 C/T 0.42 1.44E07 0.83 (0.77–0.89) C/T 0.27 2.07E04 0.79 (0.69–0.89) T/C 0.41 6.55E03 0.78 (0.65–0.93)
rs2785201 35.045414 C/G 0.42 1.70E07 0.83 (0.77–0.89) C/G 0.21 2.69E03 0.79 (0.68–0.92) G/C 0.41 5.29E03 0.77 (0.64–0.93)
rs2732546 35.045661 C/T 0.43 1.79E07 0.83 (0.77–0.89) C/T 0.27 6.04E04 0.80 (0.70–0.91) N/A N/A N/A N/A
rs1895821 35.046097 C/T 0.43 2.64E07 0.83 (0.77–0.89) C/T 0.26 3.45E04 0.79 (0.70–0.90) N/A N/A N/A N/A
rs675970 35.04692 G/A 0.42 1.78E07 0.83 (0.77–0.89) G/A 0.24 1.44E04 0.76 (0.66–0.88) N/A N/A N/A N/A
rs1834459 35.049346 A/G 0.42 6.13E07 0.83 (0.78–0.90) N/A N/A N/A N/A N/A N/A N/A N/A
rs2732544 35.049527 C/T 0.43 3.82E07 0.83 (0.77–0.89) C/T 0.26 5.98E04 0.80 (0.70–0.91) N/A N/A N/A N/A
rs2785198 35.049605 A/G 0.42 5.90E07 0.83 (0.78–0.90) A/G 0.26 6.63E04 0.80 (0.70–0.91) N/A N/A N/A N/A
rs2785197 35.049646 G/A 0.43 3.64E07 0.83 (0.77–0.89) G/A 0.26 3.95E04 0.79 (0.70–0.90) N/A N/A N/A N/A
rs1116470 35.051067 C/T 0.43 2.86E07 0.83 (0.77–0.89) C/T 0.25 1.72E04 0.77 (0.67–0.88) N/A N/A N/A N/A
rs1116471 35.051208 G/A 0.43 3.16E07 0.83 (0.77–0.89) G/A 0.25 1.96E04 0.77 (0.67–0.88) N/A N/A N/A N/A
rs2785194 35.05183 C/T 0.43 2.75E07 0.83 (0.77–0.89) C/T 0.25 1.96E04 0.77 (0.67–0.88) T/C 0.29 0.015 0.81 (0.69–0.96)
rs2785193 35.052011 C/A 0.43 2.51E07 0.83 (0.77–0.89) C/A 0.25 1.96E04 0.77 (0.67–0.88) N/A N/A N/A N/A
rs2732540 35.052062 G/A 0.44 2.57E06 0.84 (0.78–0.90) G/A 0.23 1.62E04 0.77 (0.67–0.88) N/A N/A N/A N/A
rs1834460 35.052141 C/T 0.43 3.25E07 0.83 (0.77–0.89) C/T 0.25 1.57E04 0.77 (0.67–0.88) T/C 0.29 5.40E03 0.79 (0.68–0.93)
rs2098878 35.052886 G/A 0.43 2.24E07 0.83 (0.77–0.90) G/A 0.25 1.77E04 0.77 (0.67–0.88) A/G 0.46 0.083 0.83 (0.67–1.02)
rs2553827 35.053243 A/G 0.43 4.34E07 0.83 (0.78–0.89) A/G 0.25 1.52E04 0.77 (0.67–0.88) N/A N/A N/A N/A
rs2553826 35.053334 C/T 0.43 2.49E07 0.83 (0.77–0.89) C/T 0.25 1.52E04 0.77 (0.67–0.88) N/A N/A N/A N/A
rs429503 35.053571 T/G 0.42 5.04E07 0.83 (0.78–0.90) T/G 0.23 1.94E04 0.77 (0.68–0.89) N/A N/A N/A N/A
rs63214363 35.053874 T/A 0.43 2.96E07 0.83 (0.77–0.89) N/A N/A N/A N/A N/A N/A N/A N/A
rs387619 35.054769 C/T 0.42 3.00E03 7.71E07 0.84 (0.78–0.90) 1.46E08 (0.82, 0.76–0.88) C/T 0.23 1.44E03 0.80 (0.70–0.92) C/T 0.14 0.485 0.94 (0.81–1.11)
N/A indicates SNPs that did not meet the quality control criteria after imputation.
a Lines in bold indicate observed SNPs.
b Major/minor.
c OR calculated according to the minor allele identified in the European data set.
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Figure 2. Summary of Observed and Imputed SNPs Tested at
11p13
(A and B) Regional plot of observed (A) and imputed (B) SNPs dis-
playing –log10(p) for an ~300 kb window at 11p13 with approxi-
mate gene locations given at top.
(A) Purple and red circles indicate results for SNPs observed in the
replication study. The purple diamond and red square represent
the meta-analysis results between the GWAS and the replication
study. The symbol colors indicate the strength of LD with
rs2732552, as given in the figure legend. Gray indicates that LD
information was not available. The blue trace represents the
average recombination rate for all races.
(B) The purple diamond represents the most significant SNP after
imputation, rs2553772, with strength of LD to rs2553772 indi-
cated by symbol colors as given in the legend.
(C) Expanded view of ~14 kb haplotype associated with SLE in
Europeans (blue diamonds), Asians (red squares), and African
Americans (green triangles). Black lines indicate approximate loca-
tion of transcription factor binding sites. Green and brown lines
represent approximate location of methylated H3 histones.
88 The American Journal of Human Genetics 88, 83–91, January 7, 20autoantibodies that recognize various components of the
PDH complex.19
CD44 is an ~95 kb gene with 20 exons that encodes
a cell-surface glycoprotein expressed on most immunolog-
ical cell types. Alternative splicing of this gene is excep-
tionally complex. Two constant regions of five exons flank
a central variable region consisting of ten exons, poten-
tially resulting in hundreds of protein isoforms (reviewed
in 20). These alternate splice variants are differentially
expressed across hematopoietic cells types, but what
governs this complex process is not understood. The
protein is important in lymphocyte activation, recircula-
tion and homing, apoptosis, hematopoiesis, and tumor
metastasis.20,21 CD44 can also heterodimerize with other
proteins on the cell surface and bind a diverse repertoire
of ligands (e.g., hyaluronic acid, osteopontin, collagens,
and matrix metalloproteinases).
There are data supporting a role for CD44 in the
pathogenesis of SLE and other inflammatory diseases. A
genome-wide linkage scan of multiplex SLE families
with thrombocytopenia has previously shown linkage
(LODmax ¼ 5.72) with the region that includes CD44 at
11p13.4 Linkage was independently confirmed, but anal-
ysis of four SNPs within CD44 showed no association,
which is consistent with the negative results from SNPs
within CD44 evaluated in the current study.22 Several
reports have shown differential protein expression and
complex alternative splicing of the CD44mRNA to be asso-
ciated with disease. Li et al. reported that T cells from SLE
patients overexpressed CD44 and demonstrated increased
adhesion and chemotactic migration when compared to
patients with rheumatoid arthritis (RA [MIM 180300]) or
healthy controls.23 These investigators also evaluated
kidney biopsies from patients with lupus nephritis and
with allograft kidney rejection for expression of CD44.
Although both of these tissue samples had CD3þ CD44þ
T cells, the SLE cases exhibited stronger staining for
CD44 than the allographed tissue.23 A recent study by
Crispin et al. shows that overexpression of CD44v3 and
CD44v6 isoforms in T cells was observed in SLE patients
and correlates with disease activity.24 These two splice vari-
ants are of particular interest because they have been
found to be sufficient for fibroblast-type synoviocytes of
RA patients to become invasive.25,26
CD44 is also important in the homing of T cells to the
pancreas in type 1 diabetes mellitus (MIM 222100). Inter-
estingly, nonobese diabeticmice injected withmonoclonal
antibodies against CD44 were resistant to diabetes, and
immunohistochemical analysis of the pancreas tissue of
these mice shows no active inflammation or destruction
of islet cells.27 In Sjo¨gren syndrome (MIM 270150), CD44
was found to be overexpressed in minor salivary glands
of patients in a gene expression study.28 Expression of
CD44 on macrophages, T cells, and endothelial cells in
an ApoE/ murine model of cardiovascular disease medi-
ates recruitment of inflammatory cells into atherosclerotic
lesions.2911
Figure 3. Linkage Disequilibrium Pat-
terns for the SNPs within the Associated
Region
Haplotype structure in Asians (A) and
African Americans (B) from the data
collected in this study. Diamonds show
r2 values between markers, and those in
solid black without a number are r2 ¼ 1.0.
Asian and European haplotype structure is
nearly identical.We have established genetic association with SLE to
a haplotype between PDHX and CD44. Imputation and
transethnic mapping focus the effect on an ~14 kb haplo-
type in a region of strong regulatory potential that may
influence expression of the centromeric CD44. FurtherTable 5. Reference Populations for Imputation
Populations
1000 Genomes
Panel 1 HapMap3 Panel 2
African Americans YRI YRI þ ASW þ CEU þ TSI
Asians CHB þ JPT CHB þ JPT
Europeans CEU CEU þ TSI
The following abbreviations are used: ASW, African ancestry in Southwest USA;
CEU, Utah residents with Northern and Western European ancestry from the
CEPH collection; CHB, Han Chinese in Beijing, China; JPT, Japanese in Tokyo,
Japan; TSI, Tuscans in Italy; YRI, Yorubans in Ibadan, Nigeria.
The Afunctional studies of this complex locus will be required
to determine the precise variant or variants influencing
risk and to characterize the contribution to SLE and
perhaps other immunological, inflammatory, and onco-
logic phenotypes.Supplemental Data
Supplemental Data include Supplemental Acknowledgments and
can be found with this article online at http://www.cell.com/
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